We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.1%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.83B
AUM Growth
-$798M
Cap. Flow
-$482M
Cap. Flow %
-17.04%
Top 10 Hldgs %
54.55%
Holding
115
New
16
Increased
15
Reduced
28
Closed
28

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$101M
2
BBNX
Beta Bionics
BBNX
+$29.7M
3
INSM icon
Insmed
INSM
+$27.9M
4
DYN icon
Dyne Therapeutics
DYN
+$25.3M
5
SLDB icon
Solid Biosciences
SLDB
+$21.4M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$80.9M
2
NUVL
Nuvalent
NUVL
+$77.1M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$62.8M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$62.6M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$54.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$32.1M 1.13%
792,960
-392,632
-33% -$16.6M
MRUS
27
DELISTED
Merus
MRUS
$29.1M 1.03%
690,485
+390,485
+130% +$17M
AMLX icon
28
Amylyx Pharmaceuticals
AMLX
$2.19B
$27.9M 0.98%
7,874,348
+1,100,000
+16% +$3.91M
ADMA icon
29
ADMA Biologics
ADMA
$2.02B
$27.2M 0.96%
1,373,233
+482,953
+54% +$8.35M
PCVX icon
30
Vaxcyte
PCVX
$7.65B
$26.7M 0.94%
706,567
-1,011,850
-59% -$80.9M
JANX icon
31
Janux Therapeutics
JANX
$912M
$26.2M 0.93%
970,412
+152,517
+19% +$5.75M
DYN icon
32
Dyne Therapeutics
DYN
$4.15B
$24.2M 0.85%
2,313,403
+1,770,126
+326% +$25.3M
CELC icon
33
Celcuity
CELC
$4.06B
$23.9M 0.84%
2,362,279
– –
ZYME icon
34
Zymeworks
ZYME
$1.62B
$22.2M 0.78%
1,864,672
-265,348
-12% -$3.62M
ISRG icon
35
Intuitive Surgical
ISRG
$127B
$20.1M 0.71%
40,619
-22,500
-36% -$12.4M
OBIO icon
36
Orchestra BioMed
OBIO
$228M
$19.7M 0.69%
4,592,556
– –
BBNX
37
Beta Bionics
BBNX
$676M
$19.5M 0.69%
+1,593,608
New +$29.7M
PODD icon
38
Insulet
PODD
$11.8B
$18.8M 0.66%
71,597
-160,672
-69% -$43.5M
RGEN icon
39
Repligen
RGEN
$6.91B
$16.5M 0.58%
+129,801
New +$20M
DRUG
40
Bright Minds Biosciences
DRUG
$697M
$16M 0.57%
444,649
+41,000
+10% +$1.5M
MDGL icon
41
Madrigal Pharmaceuticals
MDGL
$12.6B
$15.4M 0.54%
+46,500
New +$15.3M
INBX icon
42
Inhibrx
INBX
$1.16B
$14.9M 0.53%
1,064,026
– –
BSX icon
43
Boston Scientific
BSX
$68.4B
$13.1M 0.46%
+130,000
New +$13.1M
SION
44
Sionna Therapeutics
SION
$2.02B
$13.1M 0.46%
+1,251,101
New +$20.4M
IKT icon
45
Inhibikase Therapeutics
IKT
$347M
$13M 0.46%
5,925,000
– –
VKTX icon
46
Viking Therapeutics
VKTX
$3.88B
$12.3M 0.43%
509,005
-486,889
-49% -$15.4M
DXCM icon
47
DexCom
DXCM
$29B
$12.2M 0.43%
+178,000
New +$14.5M
NBIX icon
48
Neurocrine Biosciences
NBIX
$18.2B
$11.1M 0.39%
100,050
– –
EWTX icon
49
CALL
Edgewise Therapeutics
EWTX
$4.28B
$11M 0.39%
+500,000
New +$13.1M
XENE icon
50
Xenon Pharmaceuticals
XENE
$6.1B
$10.9M 0.39%
325,324
– –
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Perceptive Advisors held 115 positions worth $2.83B, down 22% from $3.63B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors withdrew a net $482M in Q1 2025, closing 28 positions and reducing 28 holdings. Its most notable exit was Procept Biorobotics, an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Beta Bionics worth $19.5M.

  • Perceptive Advisors's largest Q1 2025 buy was Beta Bionics: 1,593,608 shares worth $19.5M.
  • Perceptive Advisors added most to Edgewise Therapeutics in Q1 2025, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2025 reduction was Vaxcyte, cutting an estimated $80.9M.
  • Perceptive Advisors fully exited Procept Biorobotics in Q1 2025, selling an estimated $23.4M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $2.83B portfolio in Q1 2025.
  • Perceptive Advisors opened 16 new positions and closed 28 in Q1 2025.
  • Perceptive Advisors's portfolio value fell 22% quarter-over-quarter to $2.83B.

Based on Perceptive Advisors's 13F filing for Q1 2025, filed 15 May 2025.